Get the latest news in health technology, digital health and health AI with this weekly overview. News for the week from July 6th to 10th.
Samsung, Neuroscape partner in cognitive research
Samsung is partnering with Neuroscape to study changes in cognitive function across adulthood, the organizations announced Thursday.
The Neuroscape Technology for Aging Health – Digital Approaches (TAH-DA) study aims to identify biometric predictors of cognitive decline over a one-year period using Samsung wearable devices, namely the Galaxy Watch and Galaxy Tab A9. Recruitment began earlier this year, with a goal of 200 participants between the ages of 40 and 89.
“This rich dataset will allow us to determine which passive biometrics are relevant to cognitive assessments, allowing us to test the effectiveness of evidence-based digital interventions in improving cognitive function across the adult lifespan,” Neuroscape clinical director Dr. Joaquín Ángela said in a statement. “Unlike traditional neuroscience research, which often uses highly controlled, simplified stimuli and static laboratory environments, modern approaches aim to study human cognition in real-time under real-world conditions.”
Surgical Safety Technologies rebrands as a procedural ambient AI platform
Surgical Safety Technologies has rebranded to Ambient, promoting itself as the only procedural ambient AI platform that transforms the procedure environment.
Ambient is built on more than 15 million hours of real-world procedural data, the largest procedural dataset in the healthcare industry, executives said. It works across operating rooms, catheterization labs, endoscopy suites, labor and delivery, trauma and recovery.
“We built this technology because, as surgeons, we knew we couldn’t improve what we couldn’t objectively measure,” Ambient founder and CEO Theodor Grancharov, MD, said in a statement. “What started as a way to help surgeons learn and improve has become something much bigger. Today, health systems have the intelligence to not only know what happened in a case, but to perform every surgery better. Our vision is a world where every surgery moves on to the next surgery.”
According to a July 7 announcement, the platform is live in 450 treatment rooms in the U.S. and Europe, and additional features will be added.
University of California, San Diego establishes Applied Medical Intelligence Institute
UC San Diego on Monday announced the launch of the Applied Medical Intelligence Institute, a new collaboration between six schools and UC San Diego to advance data-driven and equitable health care.
The institute is built on three strategic pillars: health intelligence and implementation leadership. Training and education and innovation, results and research. Its goal is to achieve “scalable and reliable health outcomes for all” through health innovation.
“In health care, the most significant gaps are usually not a lack of innovation, but rather systemic challenges to the ‘last mile,’ integrating new discoveries into the daily flow of patient care,” Patty Maysent, CEO of UC San Diego Health, said in a statement. “By leveraging the intelligence of this institute, we will be able to reduce clinical variation and eliminate preventable harm, ensuring we are always providing the highest standards of care to all patients.”
Along with its partner schools, the institute will also work with specialized centers such as the San Diego Supercomputer Center, the Sanford Institute for Empathy and Compassion, and the Center for Healthcare Cybersecurity.
IVI RMA Global, Conceivable Life Sciences to Introduce First AI IVF Lab in 2027
Fertility organization IVI RMA Global on Thursday announced a strategic partnership with Conceivable Life Sciences to bring the world’s first auto-assisted in vitro fertilization (IVF) testing system to U.S. clinics.
Conceivable’s Aura platform is designed to work collaboratively with embryologists through real-time perception, inference, and action in a clinical environment. It is being evaluated in an ongoing pilot study, where more than 100 patients have been treated, more than 1,000 eggs have been processed, and live births have been achieved, according to a July 2 announcement.
Deployment of the platform will begin in 2027 at IVI RMA’s U.S. locations and expand across the IVI RMA network in Europe, Latin America and the Middle East.
“IVI RMA’s decision to partner with Conceivable is a defining moment for reproductive medicine and reflects something deeper than a commercial agreement,” Conceivable Life Sciences CEO and co-founder Alan Murray said in a statement. “Together, we have the opportunity to establish new benchmarks for IVF laboratory performance and bridge the gap between standard treatments available in the world’s best clinics and treatments that more patients can actually access.”
